23-MULTI-64-GUI-PMC (GCT1042-01): A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date3/6/243/6/26

Funding

  • Genmab US Incorporated: $27,556.00